$54.82
4.59% yesterday
Nasdaq, Oct 17, 10:16 pm CET
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Moderna Stock price

$54.82
-17.17 23.85% 1M
-48.62 47.00% 6M
-44.63 44.88% YTD
-31.51 36.50% 1Y
-280.02 83.63% 3Y
+40.28 277.03% 5Y
+36.22 194.73% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
-2.64 4.59%
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Key metrics

Market capitalization $21.07b
Enterprise Value $13.85b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.75
P/S ratio (TTM) P/S ratio 4.18
P/B ratio (TTM) P/B ratio 1.80
Revenue growth (TTM) Revenue growth -52.22%
Revenue (TTM) Revenue $5.04b
EBIT (operating result TTM) EBIT $-4.64b
Free Cash Flow (TTM) Free Cash Flow $-3.98b
Cash position $8.49b
EPS (TTM) EPS $-15.38
P/E forward negative
P/S forward 6.54
EV/Sales forward 4.30
Short interest 10.72%
Show more

Create a Free Account to create an Moderna alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Moderna Stock Analysis

Analyst Opinions

27 Analysts have issued a Moderna forecast:

8x Buy
30%
16x Hold
59%
3x Sell
11%

Analyst Opinions

27 Analysts have issued a Moderna forecast:

Buy
30%
Hold
59%
Sell
11%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
5,042 5,042
52% 52%
100%
- Direct Costs 3,909 3,909
20% 20%
78%
1,133 1,133
80% 80%
22%
- Selling and Administrative Expenses 926 926
0% 0%
18%
- Research and Development Expense 4,322 4,322
9% 9%
86%
-4,115 -4,115
633% 633%
-82%
- Depreciation and Amortization 528 528
46% 46%
10%
EBIT (Operating Income) EBIT -4,643 -4,643
1,230% 1,230%
-92%
Net Profit -5,867 -5,867
586% 586%
-116%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Neutral
Accesswire
about 17 hours ago
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.
Positive
Schaeffers Research
one day ago
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring.
Negative
Investors Business Daily
one day ago
Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell?
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,600
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today